Skip to content
Buy This GLP
← Research
Evidence

Semaglutide Discontinuation for Side Effects: 2.62 Times Placebo in Four Trials

In four trials, injected semaglutide produced more weight loss than placebo. Stopping because of adverse events was also more frequent.

Editorial profile: Neil SandersBuy This GLP Editorial Team5 min read
Stopping because of side effects, vs placebo1×2.62×1.704.03Relative risk and 95% confidence intervalFour trials, 3,613 participants, none with type 2 diabetes

When comparing GLP-1 side effects, it helps to separate any reported symptom from adverse events that led participants to stop treatment. This review pooled four randomized trials of injected semaglutide [1].

Weight loss and stopping treatment

The trials included 3,613 adults with overweight or obesity without type 2 diabetes. The pooled difference in weight change was 11.85 percentage points in favor of semaglutide (95% CI 10.90 to 12.81 points) [1].

Discontinuation due to adverse events was more frequent on semaglutide (risk ratio 2.62, 95% CI 1.70 to 4.03). Digestive events included nausea, vomiting, diarrhea and constipation. The review's Table 5 shows the event counts for each trial.

How the trial result applies to routine care

Studies of GLP-1 persistence in routine care also capture reasons such as cost and access. The trial estimate isolates discontinuations attributed to adverse events.

A relative risk compares groups and cannot predict an individual's chance of stopping. The trials also differ in how they enrolled participants and followed them.

Frequently asked

How much more often did people stop because of adverse events?
The pooled relative risk was 2.62. The estimate compares semaglutide with placebo across the four trials.

Sources

  1. [1] Naz F, et al. (2026). Effectiveness & safety of semaglutide in weight reduction in obese nondiabetic patients: A systematic review and meta-analysis Medicine. PMID 42536519

Where to get it

Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

Open the price desk →

More in Evidence